Study of Early Nutritional Supplementation and Exercise in Head and Neck Squamous Cell Carcinoma patients

Organizational Data

DRKS-ID:
DRKS00032370
Recruitment Status:
Recruiting planned
Date of registration in DRKS:
2024-01-26
Last update in DRKS:
2024-04-25
Registration type:
Prospective

Acronym/abbreviation of the study

SENSE-HNSCC

URL of the study

No Entry

Brief summary in lay language

This study aims to examine wether giving additional food and performing a structured home workout can positively improve the course of treatment for head and neck cancer. Patients are randomly assigned to either a pure observational group or an interventional group. The inclusion into the study is at initial presentation with a relevant suspected tumor and additional exams are performed when therapy begins and three months after concluding therapy. The actual intervention is performed until two weeks past beginning treatment which usually means 5-9 weeks.

Brief summary in scientific language

We evaluate the usefulness of multimodal prehabliotation in the treatment of head and neck cancer patients. Inclusion is on first presentation with highly probable head and neck cancer. After Assessment Patients are randomised into an intervention group and a control group. The intervention group is given high calorie drinks and receives a short home exercise program. The intervention should be performed until two weeks past treatment beginning. This should be about 5-9 Weeks overall depending on treatment modality. Followups are performed when treatment begins and three months after concluding cancer treatment.

Health condition or problem studied

ICD10:
C02.0 - Dorsal surface of tongue
ICD10:
C02.1 - Border of tongue
ICD10:
C02.2 - Ventral surface of tongue
ICD10:
C02.3 - Anterior two-thirds of tongue, part unspecified
ICD10:
C02.4 - Lingual tonsil
ICD10:
C02.8 - Overlapping lesion of tongue
ICD10:
C09.0 - Tonsillar fossa
ICD10:
C09.1 - Tonsillar pillar (anterior)(posterior)
ICD10:
C09.8 - Overlapping lesion of tonsil
ICD10:
C32.0 - Glottis
ICD10:
C32.1 - Supraglottis
Healthy volunteers:
No

Interventions, Observational Groups

Arm 1:
Intervention arm: Dietary supplements in the form of high calorie drinks independent of nutritional status and a home exercise program: - Shrugs with water bottles daily - squats into a chair daily - Use of breathing trainer daily - moderate exercise (biking, walking) for at least 30 minutes 4x a week
Arm 2:
Control arm: Nutritional Supplementation in the form of high calorie drinks when there is malnutrition by GLIM criteria. The manual on the exercises used in the study is given to the patients without requesting their implementation: - Shrugs with water bottles daily - squats into a chair daily - Use of breathing trainer daily - moderate exercise (biking, walking) for at least 30 minutes 4x a week

Endpoints

Primary outcome:
- Change in body composition at the followup three months after conclusion therapy - Change in bodily fitness at the followup three months after conclusion therapy
Secondary outcome:
- Prevalence of delayed discharge and radiation delays - Quality of life differences - Changes in laboratory parameters - Changes in transcriptome and metabolome - Differences in immune modulation - Changes in movement data

Study Design

Purpose:
Supportive care
Allocation:
Randomized controlled study
Control:
  • Active control (effective treatment of control group)
Phase:
N/A
Study type:
Interventional
Mechanism of allocation concealment:
Patients are randomized after consent
Blinding:
No
Assignment:
Parallel
Sequence generation:
Randomization Module in REDCap
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting planned
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Monocenter study
Recruitment location(s):
  • University medical center Universitätsmedizin Greifswald Greifswald

Recruitment period and number of participants

Planned study start date:
2024-06-01
Actual study start date:
No Entry
Planned study completion date:
2026-03-31
Actual Study Completion Date:
No Entry
Target Sample Size:
70
Final Sample Size:
No Entry

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
no maximum age
Additional Inclusion Criteria:
- Able to perform exercises - Able to comply with study documentation

Exclusion Criteria

- Patients at risk of injury when complying with the exercise regime - Patients with poorly managed diabetes - Patients unable to give written consent

Addresses

Primary Sponsor

Address:
Universitätsmedizin Greifswald
Ferdinand-Sauerbruch Str
17475 Greifswald
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.medizin.uni-greifswald.de/de/home/
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Universitätsmedizin Greifswald
Dr. med. Markus Blaurock
Ferdinand-Sauerbruch-Str.
17475 Greifswald
Germany
Telephone:
03834866236
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Contact for Public Queries

Address:
Universitätsmedizin Greifswald
Dr. med. Markus Blaurock
Ferdinand-Sauerbruch-Str.
17475 Greifswald
Germany
Telephone:
03834866236
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Principal Investigator

Address:
Universitätsmedizin Greifswald
Dr. med. Markus Blaurock
Ferdinand-Sauerbruch-Str.
17475 Greifswald
Germany
Telephone:
03834866236
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Sources of Monetary or Material Support

Institutional budget, no external funding (budget of sponsor/PI)

Address:
Universitätsmedizin Greifswald
17475 Greifswald
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Ethics Committee

Address Ethics Committee

Address:
Ethikkommission an der Universitätsmedizin Greifswald, Institut für Pharmakologie
Felix-Hausdorff-Straße 3
17487 Greifswald
Germany
Telephone:
+49-3834-865644
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www2.medizin.uni-greifswald.de/ethik/

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2023-11-19
Ethics committee number:
BB 184/23
Vote of the Ethics Committee:
Approved
Date of the vote:
2023-12-08

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry